Approval · Notice of Compliance 29024 · 2022
PRO-APIXABAN: Notice of Compliance 29024
Issued September 20, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29024
- Date
- September 20, 2022
- Company
- Pro Doc LimiteeLaval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between Two Companies
- Canadian reference product
- ELIQUIS (Bristol-Myers Squibb Canada)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRO-APIXABAN | 02530724 | Marketed |
| PRO-APIXABAN | 02530732 | Marketed |